# RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

> **NCT07030569** · — · RECRUITING · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 500 (estimated)

## Conditions studied

- Radiomic
- Radiomics
- Breast Cancer Metastatic
- Breast Cancer Stage IV
- Breast Carcinoma
- Breast Neoplasms
- Breast Cancer
- Breast Cancer With Bone Metastasis
- Breast Cancer With Metastatic Bone Disease
- Trastuzumab
- HER2
- HER2 + Breast Cancer
- HER2 Positive Breast Carcinoma
- HER2-positive Breast Cancer
- Her2/Neu Positive Advanced Solid Tumors
- HER2/Neu-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan (DS-8201a)

## Key facts

- **NCT ID:** NCT07030569
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030569, "RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07030569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*